Literature DB >> 8397461

Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines.

W H Kim1, C Y Chon, Y M Moon, J K Kang, I S Park, H J Choi.   

Abstract

Several anticancer chemotherapeutic agents (5-fluorouracil, adriamycin and cisplatinum) and desferrioxamine, an iron chelator, were tested with regard to cytotoxicity and to the combined effect on radiation induced cell killing using two human hepatoma cell lines (HepG2 and PLC/PRF/5). Survival fractions were measured by quantitative colorimetric assay (MTT assay) and dose-response curves were plotted. MTT assay could be successfully used in the assessment of radiosensitivity in addition to chemosensitivity, because a good linear relationship between optical densities and cell numbers was observed and cells approached exponential growth for the first 7 days of culture when 5 x 10(3) or less cells were inoculated per well in our study. Steepness of the final slope (D0), width of the shoulder (D0) and the extrapolation number (n) of radiation survival curves were 1061.72 rad, 226.43 rad and 1.25 respectively in HepG2 and 1091.38 rad, 268.42 rad and 1.29 respectively in PLC/PRF/5. After combining anticancer chemotherapeutic agents and desferrioxamine with radiation, the widths of the shoulders were decreased whereas sensitizer enhancement ratios were increased as the concentration of drugs increased in both cell lines. These results suggest that neither anticancer chemotherapeutic agents nor desferrioxamine enhance cell killing induced by radiation alone, but suggested the possibility that they inhibit the repair of radiation damage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397461     DOI: 10.3349/ymj.1993.34.1.45

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  9 in total

1.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma.

Authors:  J Chen; T Lan; W Zhang; L Dong; N Kang; S Zhang; M Fu; B Liu; K Liu; C Zhang; J Hou; Q Zhan
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

3.  IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.

Authors:  Jie Yang; Zhi Zeng; Yuyu Peng; Jianhua Chen; Ling Pan; Deshun Pan
Journal:  Histochem Cell Biol       Date:  2014-04-26       Impact factor: 4.304

4.  Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes.

Authors:  Bing Liu; Genshu Wang; Jie Yang; Xuediao Pan; Zhicheng Yang; Linquan Zang
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

5.  The Cell Survival of F10B16 Melanoma and 4T1 Breast Adenocarcinoma Irradiated to Gamma Radiation Using the MTT Assay Based on Two Different Calculation Methods.

Authors:  Safoora Nikzad; Bijan Hashemi; Zuhair-Mohammad Hassan; Hossein Mozdarani
Journal:  J Biomed Phys Eng       Date:  2013-06-01

6.  In vitro Cytotoxicity Effects of 197Au/PAMAMG4 and 198Au/PAMAMG4 Nanocomposites Against MCF7 and 4T1 Breast Cancer Cell Lines.

Authors:  Simin Janitabar-Darzi; Reza Rezaei; Kamal Yavari
Journal:  Adv Pharm Bull       Date:  2017-04-13

7.  Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro.

Authors:  Yaser H Gholami; Kathy P Willowson; Nicholas J Forwood; Rozelle Harvie; Nicholas Hardcastle; Regina Bromley; HyunJu Ryu; Samuel Yuen; Viive M Howell; Zdenka Kuncic; Dale L Bailey
Journal:  EJNMMI Phys       Date:  2018-09-03

8.  Successful development of small diameter tissue-engineering vascular vessels by our novel integrally designed pulsatile perfusion-based bioreactor.

Authors:  Lei Song; Qiang Zhou; Ping Duan; Ping Guo; Dianwei Li; Yuan Xu; Songtao Li; Fei Luo; Zehua Zhang
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

Review 9.  Targeting iron metabolism in cancer therapy.

Authors:  Michael Morales; Xiang Xue
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.